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Highly virulent influenza virus infection results in excessive cytokine production, recruitment of
leukocytes, and immune-mediated pulmonary injury. Teijaro et al. (2011) now demonstrate that
sphingosine-1-phosphate receptor 1 ligands suppress all features of flu-inflicted pathological
inflammation and place the endothelium at the center of this regulatory network.Recognition and rapid clearance of path-
ogens by the innate immune system pro-
vide the first line of defense in metazoan
organisms. However, excessive activa-
tion of the innate immune system in
response to pathogens can lead to patho-
logical inflammatory consequences. In
the case of highly virulent 1918 and avian
H5N1 influenza virus infections, early
recruitment of inflammatory leukocytes
to the lung, followed by excessive early
cytokine responses (known as a cytokine
storm), is considered to be the key con-
tributor to morbidity and mortality of the
infection (Tscherne and Garcı´a-Sastre,
2011). Likewise, the virulence of the pan-
demic 2009 H1N1 ‘‘swine flu’’ is associ-
ated with viral replication in the lower
respiratory tract and more severe pulmo-
nary damage compared to seasonal flu
(Tscherne and Garcı´a-Sastre, 2011).
However, the cell types that are respon-
sible for the initiation and amplification of
the cytokine storms that follow virulent
influenza infection remain unclear. In this
issue, Teijaro et al. (2011) have uncovered
an unexpected role of endothelial cells in
coordinating the inflammatory sequelae
via sphingosine-1-phosphate signaling.
Sphingosine-1-phosphate is a metabo-
lite of sphingolipid and is a ligand for a
family of five G protein-coupled recep-
tors, S1P1–5 (Rosen et al., 2009). Differ-
ential expression of these receptors
enables control of angiogenesis, heart
development, and immunity in a highly
specific manner. The sphingosine analog
FTY720, a well-known immunomodulator
that has recently been approved for the
treatment of multiple sclerosis, is phos-
phorylated in vivo by sphingosine kinase
2 to produce a ligand for the S1P re-ceptors S1P1, 3–5. Its mode of action is
through sequestration of lymphocytes in
lymph nodes away from peripheral sites
of inflammation. Prolonged exposure to
FTY720 causes S1P1 endocytosis and
degradation, impairing the ability of
lymphocytes to respond to endogenous
S1P to egress out of lymph nodes (Cyster,
2005).
The study by Teijaro et al. (2011) fol-
lowed up on previous findings by the
same group that local intratracheal instil-
lation of S1P ligands reduces cytokine
responses following respiratory infections
with a mouse-adapted influenza virus
(Marsolais et al., 2008, 2009) or human
2009 H1N1 influenza isolate (Walsh
et al., 2011). These studies also revealed
that the S1P1-specific agonists do not
affect the generation of adaptive immune
responses (CD8 T cells and neutralizing
antibodies) and do not alter viral replica-
tion in vivo (Marsolais et al., 2008). Using
S1P1-specific agonists, the current
study shows that stimulation of S1P1
alone recapitulates much of the suppres-
sive phenotype of AAL-R, which is a
broad-spectrum agonist of S1P recep-
tors. Notably, intratracheal instillation of
CYM-5442 (an S1P1 agonist) on hours 1,
13, 25, and 37 of influenza virus challenge
significantly dampened type I interferon
(IFN), cytokine, and chemokine release
into the bronchoalveolar lavage (BAL)
and resulted in a significant decrease in
infiltration of monocytes, macrophages,
neutrophils, and natural killer (NK) cells
into the lung. In addition, oral administra-
tion of another S1P1 agonist, RP-002, at
1 and 25 hr after infection resulted in
increased survival of mice challenged
with 2009 H1N1 human isolate (Figure 1).Cell 146, SeTo address the mechanism of action,
the authors examined the expression of
S1P1 using S1P1-eGFP knockin mice
(Cahalan et al., 2011). As reported previ-
ously, in addition to lymphocytes, a high
level of S1P1 expression was found on
lymphatic and vascular endothelial cells
isolated from the lung (Cahalan et al.,
2011). However, influenza-induced cyto-
kine responses and cellular recruitment
to the lung were blocked by CYM-5442
in RAG2-deficient mice (devoid of T and
B lymphocytes), suggesting that S1P1
stimulation dampens innate immune res-
ponses in a manner that is independent
of its well-known function in lymphocyte
sequestration.
Next, the authors demonstrated that
production of chemokines CCL2, CCL5,
and CXCL10 from vascular and lymphatic
endothelium following influenza infection
was significantly reduced by CYM-5442
treatment in vivo. Intratracheal instillation
of recombinant CCL2 restored monocyte,
macrophage, and NK cell recruitment
to the lung of mice treated with CYM-
5442. Surprisingly, CCL2 was not suffi-
cient to restore IFN or cytokine responses
in the lung. Further, depletion of CD11b+
cells (including monocytes, macro-
phages, neutrophils, and NK cells) using
antibody treatment only resulted in reduc-
tion in IFN-g secretion but did not affect
the levels of IFN-a, CCL2, IL-6, or TNF-a
in the lung. These data indicate that
inflammatory leukocyte recruitment is
not sufficient for cytokine storm in the
face of CYM-5442 treatment and is not
required for the production of the majority
of the cytokines in response to influenza
infection. Finally, type I IFNs were
placed upstream of the cytokine stormptember 16, 2011 ª2011 Elsevier Inc. 861
Figure 1. Suppression of Inflammation by S1P1 Agonists
Influenza virus infects the lung epithelial cells and subsequently alveolar
macrophages and other leukocytes. This results in type I IFN, cytokine, and
chemokine secretion by various cell types both resident and recruited. S1P1
ligands, CYM05442 and RP-002, engage S1P1 on vascular and lymphatic (not
shown) endothelial cells and block chemokine secretion from endothelial cells,
which, in turn, block recruitment of leukocytes to the lung. In addition, S1P1
signaling suppresses type I IFN, cytokine, and chemokine secretion from other
cells, resulting in reduced immunopathology. However, S1P1 agonists do not
impair dendritic cell activation, thereby enabling T cell and B cell responses to
be initiated in the draining lymph node.during influenza infection, as
IFNabR-deficient mice failed
to secrete type I IFN, chemo-
kines, or cytokines despite
the normal recruitment of
inflammatory leukocytes.
The results of this study
reveal an important role of
S1P1 as a regulator of inflam-
mation but also raise a host of
questions. First, how does
S1P1 agonism result in global
suppression of cytokines?
This may occur both at the
cell-intrinsic level within the
lung endothelial cells and at
the cell-extrinsic level in the
recruited leukocytes. S1P1
receptor is coupled to GaI,
and receptor engagement
triggers a multitude of down-
stream signaling pathways,
including PI3K and Rac acti-
vation and promoting cell
survival, motility, and barrier
functions. S1P1 also activates
the MAP kinase and phos-
pholipase C pathways and
intracellular mobilization of
calcium signaling, resulting
in cell proliferation and cyto-
kine secretion (Rosen et al.,
2009). However, it remains
unclear whether any of these
pathways directly inhibit cyto-
kine and chemokine produc-tion by endothelial cells or, alternatively,
whether S1P1-activated endothelial cells
produce anti-inflammatory mediators. It
is also possible that the anti-inflammatory
effect of S1P1 engagement is an indirect
consequence of its effect on vascular
integrity.
Second, why doesn’t the endogenous
S1P in the blood or lymph, which is
maintained at high concentration (100–
1,000 nM in blood and 30–300 nM in
lymph), trigger a similar response in the
endothelial cells? Unlike S1P, the syn-
thetic agonists of S1P1, including
CYM-5442, induce prolonged signaling,
polyubiquitination of S1P1 followed by
degradation in the lysosomes (Rosen862 Cell 146, September 16, 2011 ª2011 Elset al., 2009). Whether endocytosis and
degradation of S1P1 are requisite for
immunosuppression by CYM-5442 and
other S1P1 agonists remains to be deter-
mined. In this regard, it is interesting to
speculate whether similar blockade of
inflammation is caused by FTY720 and
whether the clinical effects of this com-
pound may, in part, depend on mecha-
nisms that extend beyond lymphocyte
sequestration.
Following seasonal influenza infection,
the virus replicates primarily in the lung
epithelium, followed by infection of alveo-
lar macrophages, dendritic cells, NK cells,
and B cells (Manicassamy et al., 2010)
(Figure 1). In contrast, H5N1 avian fluevier Inc.targets specifically endothe-
lial cells for replication in birds
(Feldmann et al., 2000). Thus,
it would be interesting to ex-
amine whether S1P1 agonists
will be effective in the case of
H5N1 influenza. Finally, the
possible role of endothelial
S1P1 in other conditions
associated with excessive
cytokine production would
be an exciting question for
future studies.REFERENCES
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